Oculis Holding Ag (OCS) Stock Price, Quote & News

Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease m...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 41 711 3960

Website: oculis.com

Address:

Bahnhofstrasse 20, Zug, Switzerland

DidYouReadThis Aug. 14 at 4:14 AM

$EYPT $OCS $EYE What did the right eye say to the left eye?

1 · Reply

justiceforb_85 Aug. 6 at 10:34 PM

$OCS positive company update overall. Not as thrilled about licaminlimab as privosegtor is the company's significant MOAT and should receive priority.

0 · Reply

OpenOutcrier Aug. 3 at 12:21 PM

$OCS (+5.2% pre) Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses https://ooc.bz/l/109609

0 · Reply

Robere Aug. 3 at 8:20 AM

$OCS news

0 · Reply

FetchDog Jul. 23 at 3:23 PM

$OCS Bought (yesterday) my starter position at $11.36. Good time to slowly accumulate.

0 · Reply

caronte Jul. 17 at 7:41 PM

$OCS is anyone following this tick?

1 · Reply

caronte Jul. 14 at 2:50 PM

$OCS why moved back to 13 from 14?

0 · Reply

G101SPM Jul. 13 at 7:31 PM

#SHOWTIME International Society on Thrombosis and Haemostasis Congress (July 14) Scheduled to appear: $COAG Ophthalmology Innovation Source Retina Innovation Summit (July 14) Scheduled to appear: $OCUL, $OCGN, $OCS

0 · Reply

justiceforb_85 Jul. 2 at 11:10 PM

$OCS recovering nicely. Dry eye candidate not as exciting as privosegtor for ON, the latter with significant preliminary efficacy data and a niche drug.

0 · Reply

VeltrixCapitalOfficial Jul. 2 at 3:56 PM

High Confidence 🚨 $OCS 15 Call 7/17 at 0.65

0 · Reply

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

OCS

Aug 10, 2026, 3:01 AM EDT - 9 days ago

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Company

OCS

Aug 6, 2026, 4:05 PM EDT - 13 days ago

Oculis Reports Q2 2026 Financial Results and Provides Company Update

OCS

Aug 6, 2026, 4:00 PM EDT - 13 days ago

Oculis Holding AG Earnings release: Q2 2026

Aug 3, 2026, 4:00 AM EDT - 16 days ago

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

OCS

Jul 2, 2026, 4:00 AM EDT - 6 weeks ago

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

OCS

Jun 11, 2026, 4:00 AM EDT - 2 months ago

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

OCS

Jun 9, 2026, 4:00 PM EDT - 2 months ago

Oculis Holding AG Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 4:00 AM EDT - 2 months ago

Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease

OCS

Jun 8, 2026, 2:45 PM EDT - 2 months ago

Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference

OCS

Jun 4, 2026, 7:00 AM EDT - 2 months ago

Oculis Holding AG Slides: Study update presentation

Jun 2, 2026, 11:23 AM EDT - 2 months ago

Oculis Holding AG Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses

OCS

Jun 1, 2026, 8:00 AM EDT - 2 months ago

Oculis Holding AG Slides: Corporate presentation

May 29, 2026, 4:30 PM EDT - 2 months ago

Oculis Holding AG Transcript: Study result

May 29, 2026, 4:30 PM EDT - 2 months ago

Oculis Holding AG Press release: Study result

May 29, 2026, 4:30 PM EDT - 2 months ago

Oculis Holding AG Slides: Study result

May 29, 2026, 3:06 PM EDT - 2 months ago

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

OCS

May 14, 2026, 4:05 PM EDT - 3 months ago

Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors

OCS

May 13, 2026, 6:00 AM EDT - 3 months ago

Oculis Holding AG Transcript: AGM 2026

May 13, 2026, 6:00 AM EDT - 3 months ago

Oculis Holding AG Slides: FY 2026

May 11, 2026, 4:05 PM EDT - 3 months ago

Oculis Reports Q1 2026 Financial Results and Provides Company Update

OCS

May 11, 2026, 1:00 AM EDT - 3 months ago

Oculis Holding AG Earnings release: Q1 2026

May 7, 2026, 4:57 AM EDT - 3 months ago

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

OCS

May 5, 2026, 4:00 AM EDT - 3 months ago

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

OCS

May 1, 2026, 4:00 AM EDT - 3 months ago

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

OCS

Apr 21, 2026, 4:05 PM EDT - 4 months ago

Oculis Publishes Invitation to the Annual General Meeting

OCS

Apr 20, 2026, 4:00 AM EDT - 4 months ago

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

OCS

Apr 14, 2026, 9:30 AM EDT - 4 months ago

Oculis Holding AG Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 7, 2026, 4:00 AM EDT - 4 months ago

Oculis to Participate in Upcoming Investor Conferences

OCS

Mar 31, 2026, 5:00 AM EDT - 5 months ago

Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis

OCS

Mar 16, 2026, 5:00 AM EDT - 5 months ago

Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting

OCS

Mar 10, 2026, 10:40 AM EDT - 5 months ago

Oculis Holding AG Transcript: Leerink Global Healthcare Conference 2026

Mar 5, 2026, 4:00 AM EST - 5 months ago

Oculis Publishes 2025 Consolidated Financial Statements

OCS

Mar 3, 2026, 4:05 PM EST - 6 months ago

Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update

OCS

Mar 3, 2026, 4:00 PM EST - 6 months ago

Oculis Holding AG Annual report: Q4 2025

Mar 3, 2026, 4:00 PM EST - 6 months ago

Oculis Holding AG Earnings release: Q4 2025

Mar 3, 2026, 4:00 PM EST - 6 months ago

Oculis Holding AG Annual report: Q4 2025

Feb 18, 2026, 4:05 PM EST - 6 months ago

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated

OCS

Feb 17, 2026, 4:00 AM EST - 6 months ago

Oculis Appoints Katie Kazem as Chief Legal Officer

OCS

Jan 14, 2026, 4:30 PM EST - 7 months ago

Oculis Holding AG Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 4:30 PM EST - 7 months ago

Oculis Holding AG Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 4:00 AM EST - 7 months ago

Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference

OCS

Jan 6, 2026, 4:00 AM EST - 8 months ago

Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis

OCS

Nov 12, 2025, 2:00 PM EST - 10 months ago

Oculis Holding AG Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 12:30 PM EST - 10 months ago

Oculis Holding AG Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 4:05 PM EST - 10 months ago

Oculis Reports Q3 2025 Financial Results and Provides Company Update

OCS

Nov 10, 2025, 4:00 PM EST - 10 months ago

Oculis Holding AG Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 10 months ago

Oculis Holding AG Registration statement: Registration Filing

Nov 5, 2025, 4:00 AM EST - 10 months ago

Oculis to Participate in Upcoming November Investor Conferences

OCS

Oct 30, 2025, 4:30 AM EDT - 10 months ago

Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development

OCS

Oct 14, 2025, 4:00 AM EDT - 11 months ago

Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025

OCS

Oct 6, 2025, 8:30 AM EDT - 11 months ago

Oculis Holding AG Transcript: Status Update

Oct 6, 2025, 8:30 AM EDT - 11 months ago

Oculis Holding AG Press release: Status Update

Oct 6, 2025, 8:30 AM EDT - 11 months ago

Oculis Holding AG Slides: Status Update

Oct 6, 2025, 4:07 AM EDT - 11 months ago

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

OCS

Sep 26, 2025, 4:05 PM EDT - 11 months ago

Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities

OCS

Sep 22, 2025, 4:00 AM EDT - 11 months ago

Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS

OCS

Sep 9, 2025, 3:45 PM EDT - 1 year ago

Oculis Holding AG Transcript: Baird Global Healthcare Conference 2025

Sep 8, 2025, 2:30 PM EDT - 1 year ago

Oculis Holding AG Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 1:00 PM EDT - 1 year ago

Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025

OCS

Sep 1, 2025, 4:00 AM EDT - 1 year ago

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

OCS

Aug 28, 2025, 4:00 AM EDT - 1 year ago

Oculis to Participate in Upcoming September Investor Conferences

OCS

Aug 25, 2025, 4:00 AM EDT - 1 year ago

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D.

OCS

Aug 21, 2025, 4:05 PM EDT - 1 year ago

Oculis Reports Q2 2025 Financial Results and Provides Company Update

OCS

Aug 21, 2025, 4:00 PM EDT - 1 year ago

Oculis Holding AG Earnings release: Q2 2025

Aug 13, 2025, 11:00 AM EDT - 1 year ago

Oculis Holding AG Transcript: Fireside Chat

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Oculis Holding AG Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 12, 2025, 4:00 AM EDT - 1 year ago

Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

OCS

Aug 12, 2025, 4:00 AM EDT - 1 year ago

Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference

OCS

Aug 1, 2025, 4:00 AM EDT - 1 year ago

Oculis Upsized Loan Facility to Access up to CHF 100 million

OCS

DidYouReadThis Aug. 14 at 4:14 AM

$EYPT $OCS $EYE What did the right eye say to the left eye?

1 · Reply

justiceforb_85 Aug. 6 at 10:34 PM

$OCS positive company update overall. Not as thrilled about licaminlimab as privosegtor is the company's significant MOAT and should receive priority.

0 · Reply

OpenOutcrier Aug. 3 at 12:21 PM

$OCS (+5.2% pre) Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses https://ooc.bz/l/109609

0 · Reply

Robere Aug. 3 at 8:20 AM

$OCS news

0 · Reply

FetchDog Jul. 23 at 3:23 PM

$OCS Bought (yesterday) my starter position at $11.36. Good time to slowly accumulate.

0 · Reply

caronte Jul. 17 at 7:41 PM

$OCS is anyone following this tick?

1 · Reply

caronte Jul. 14 at 2:50 PM

$OCS why moved back to 13 from 14?

0 · Reply

G101SPM Jul. 13 at 7:31 PM

0 · Reply

justiceforb_85 Jul. 2 at 11:10 PM

$OCS recovering nicely. Dry eye candidate not as exciting as privosegtor for ON, the latter with significant preliminary efficacy data and a niche drug.

0 · Reply

VeltrixCapitalOfficial Jul. 2 at 3:56 PM

High Confidence 🚨 $OCS 15 Call 7/17 at 0.65

0 · Reply

ApexEquityVault Jul. 2 at 3:47 PM

$OCS 15 Call 7/17 at 0.65

0 · Reply

chartistmind Jun. 30 at 7:58 PM

$OCS it is official, another 20%+ 🚀 ripper within just days memorialized into the stocktits records.

0 · Reply

crabbypatty31 Jun. 30 at 4:12 PM

$OCS Happily, this has been a great trade after the fall. Holding a nice position from here forward:))

0 · Reply

chartistmind Jun. 29 at 9:20 PM

$OCS fam, it’s done. We got another 10%+ 🐌 🚀 ripper within weeks on this garbage.

0 · Reply

G101SPM Jun. 25 at 7:39 PM

#SHOWTIME European Academy of Neurology Congress (June 26) Scheduled to appear: $IMUX, $OCS United Therapeutics Corporation Annual General Meeting (June 26) Scheduled to appear: $UTHR Aon Plc Class A Annual General Meeting (June 26) Scheduled to appear: $AON

0 · Reply

MesserschmittBavaria Jun. 24 at 6:19 PM

$OCS I’ll re wait for 4$

0 · Reply

Champi2305 Jun. 17 at 5:23 PM

$OCS https://investors.oculis.com/news-releases/news-release-details/oculis-publishes-notifications-transactions-persons-32/

0 · Reply

StreetwiseReports Jun. 16 at 4:03 PM

Oculis Holding AG Pioneers Genotype-Based Precision Approach to Dry Eye Disease Treatment https://ow.ly/rWFm50ZcntE Oculis Holding AG launches the PREDICT-1 trial for licaminlimab, targeting patients with a specific TNFR1 genotype to address unmet needs in the large dry eye disease market. $OCS

0 · Reply

StreetwiseReports Jun. 15 at 4:08 PM

Biopharma Co. Trials Precision Medicine Breakthrough for Dry Eye Disease. Gets Positive Results https://ow.ly/7AEF50ZbUXu Oculis Holding AG ( $OCS ) launches PREDICT-1, a genotype-based trial for licaminlimab, targeting 10M moderate-to-severe dry eye patients.

0 · Reply

justiceforb_85 Jun. 12 at 11:02 PM

$OCS feel like company should focus on privosegtor in ON. Not as confident on their dry eye asset.

0 · Reply

ClassiTrader Jun. 10 at 4:49 PM

$OCS 👀🃏

0 · Reply

JohnnySecretz Jun. 9 at 6:08 PM

$OCS $9.20 then ded cat to $13

0 · Reply

Market Cap	764.81M
Revenue (ttm)	1.45M
Net Income (ttm)	-119.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-8,237.24%
Debt to Equity Ratio	0.00

Volume	272,100
Avg Vol	413,670
Day's Range	N/A - N/A
Shares Out	57.98M
Stochastic %K	91%
Beta	0.51
Analysts	Strong Sell
Price Target	$36.60